Krystal Biotech (NASDAQ:KRYS) CAO Kathryn Romano Sells 12,500 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares of the company’s stock, valued at $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $272.65 on Thursday. The firm has a market capitalization of $7.91 billion, a PE ratio of 40.88 and a beta of 0.49. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $295.98. The firm’s 50-day moving average is $260.24 and its two-hundred day moving average is $204.03.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. The Goldman Sachs Group upped their price objective on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $310.00 price objective (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Zacks Research lowered shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and a consensus price target of $277.89.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in the business. Edgestream Partners L.P. purchased a new position in Krystal Biotech during the 2nd quarter worth $2,705,000. EFG Asset Management North America Corp. boosted its stake in shares of Krystal Biotech by 18.4% during the third quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after buying an additional 4,217 shares during the period. Voya Investment Management LLC boosted its stake in shares of Krystal Biotech by 46.7% during the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock worth $16,578,000 after buying an additional 29,915 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in shares of Krystal Biotech by 45.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after buying an additional 4,682 shares during the last quarter. Finally, Norges Bank acquired a new position in Krystal Biotech in the 2nd quarter valued at about $38,861,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.